Challenges and considerations in diagnosing the kidney disease in deteriorating graft function

Transplant International

Volumn 25, Issue 11, 2012, Pages 1119-1128

  Ekberg, Henrik ^a   Johansson, Martin E ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

calcineurin inhibitor; graft failure; nephrotoxicity; transplantation

Indexed keywords

CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CREATININE; CYCLOSPORIN; HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

CAUSE OF DEATH; CHRONIC ALLOGRAFT NEPHROPATHY; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HYALINE DEGENERATION; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; LONG TERM CARE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; POLYOMA VIRUS; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; REVIEW; THROMBOSIS;

CALCINEURIN; ENZYME INHIBITORS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 84867529594     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01516.x     Document Type: Review

References (47)

1. Collaborative Transplant Study. CTS Outcome Graphs. 2011; Graph K-14103E-0711. Available at: http://www.ctstransplant.org/public/introduction. shtml. Accessed 11 June 2012.
2. Lamb KE, Lodhi S, Meier-Kriesche HU,. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450.
3. Gill JS, Tonelli M,. Penny wise, pound foolish? Coverage limits on immunosuppression after kidney transplantation. N Engl J Med 2012; 366: 586.
4. Kirk AD, Knechtle SJ, Larsen CP, Newell KA, Pearson TC,. Miles to go. Am J Transplant 2011; 11: 1119.
5. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
6. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010; 10: 2066.
7. Sellarés J, de Freitas DG, Mengel M, et al. Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant 2011; 11: 489.
8. Nankivell BJ, Kuypers DR,. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378: 1428.
9. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB,. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
10. Racusen LC, Regele H,. The pathology of chronic allograft dysfunction. Kidney Int 2010; 78 (Suppl 119): S27.
11. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
12. Acott P, Babel N,. BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? Ann Transplant 2012; 17: 86.
13. Mengel M, Mihatsch M, Halloran PF,. Histological characteristics of calcineurin inhibitor toxicity-there is no such thing as specificity! Am J Transplant 2011; 11: 2549.
14. Naesens M, Kuypers DR, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481.
15. Snanoudj R, Royal V, Elie C, et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11: 2635.
16. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
17. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study. Am J Transplant 2010; 10: 324.
18. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
19. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
20. Chapman JR,. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011; 11: 693.
21. Matas AJ,. Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am J Transplant 2011; 11: 687.
22. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
23. Sharma A, Jain S, Gupta R, Guleria S, Agarwal S, Dinda A,. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies. Indian J Pathol Microbiol 2010; 53: 651.
24. Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11: 698.
25. Matas AJ, Leduc R, Rush D, et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. Am J Transplant 2010; 10: 315.
26. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD,. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464.
27. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
28. Schwarz A, Haller H, Schmitt R, et al. Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues. Am J Transplant 2010; 10: 2017.
29. Kim JY, Akalin E, Dikman S, et al. The variable pathology of kidney disease after liver transplantation. Transplantation 2010; 89: 215.
30. Pinney SP, Balakrishnan R, Dikman S, et al. Histopathology of renal failure after heart transplantation: a diverse spectrum. J Heart Lung Transplant 2012; 31: 233.
31. Gaston RS,. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009; 4: 2029.
32. Ekberg H, Grinyõ J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 2007; 7: 560.
33. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633.
34. Friman S, Arns W, Nashan B, et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant 2011; 11: 1444.
35. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
36. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
37. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
38. Arias M, Serõn D, Moreso F, Bestard O, Praga M,. Chronic renal allograft damage: existing challenges. Transplantation 2011; 91: S4.
39. Lerut E, Kuypers DR, Verbeken E, et al. Acute rejection in non-compliant renal allograft recipients: a distinct morphology. Clin Transplant 2007; 21: 344.
40. Opelz G, Döhler B,. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008; 86: 371.
41. Cross NB, Webster AC, Masson P, O'Connell PJ, Craig JC,. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88: 7.
42. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561.
43. Kobayashi T, Katayama A, Kohara S, et al. Enzyme-linked immunosorbent assay for human leukocyte antigen antibody detection and urine protein test recommended for follow-up monitoring after renal transplantation. Transplantation 2008; 85: 1595.
44. Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK,. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 2011; 12: 579.
45. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555.
46. Webber A, Hirose R, Vincenti F,. Novel strategies in immunosuppression: issues in perspective. Transplantation 2011; 91: 1057.
47. Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P,. Proteasome inhibitor therapy for antibody-mediated rejection. Pediatr Transplant 2011; 15: 548.